Scott B. Ullem - 03 May 2024 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, Chief Financial Officer
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
03 May 2024
Transactions value $
-$431,671
Form type
4
Filing time
06 May 2024, 19:18:32 UTC
Previous filing
30 Apr 2024
Next filing
09 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Tax liability -$53,928 -634 -3.32% $85.06 18,440 03 May 2024 Direct
transaction EW Common Stock Options Exercise $0 +7,465 +40.48% $0 25,905 04 May 2024 Direct F1
transaction EW Common Stock Tax liability -$377,742 -4,431 -17.1% $85.25 21,474 04 May 2024 Direct
holding EW Common Stock 266,318 03 May 2024 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Performance Rights Options Exercise $0 -7,465 -100% $0* 0 04 May 2024 Common Stock 7,465 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.